Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.

Competing Interests: Conflicts of interest Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Bausch Health, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Dr Vender has received grants/research support from Abbvie, Amgen, Centocor, Dermira, Dermavant, Galderma, GSK, Leo, Lilly, Takeda, Novartis, Merck, Pfizer, Regeneron, and UCB. Dr Vender has also received honoraria and consulting fees from Abbvie, Amgen, Janssen, Galderma, GSK, Leo, Lilly, Novartis, Pfizer, Bausch-Health, Actelion, Celgene, Cipher, and UCB. Dr Turchin has received honoraria and consulting fees from Abbvie, Bausch Health, Celgene, Amgen, Eli Lilly, Janssen, LeoPharma, Novartis, and UCB. Dr Turchin has also been involved in clinical trials sponsored by Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LeoPharma, and Novartis. Dr Shukla has received honoraria and consulting fees from Abbvie, Amgen, Bausch, Galderma, Janssen, Leo, Lily, Novartis, Pfizer, Sanofi, and UCB. Dr Hong is a researcher/consultant/advisor for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingleheim, Bristol-Meyer Squibb, Celgene, Dermira, Dermavant, DS Biopharma, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, and UCB. Dr Maari is an investigator, Advisory Board Member, Speaker, Consultant for, and received honoraria or grants from Abbvie, UCB, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Leo Pharma, GSK-Stiefel, Janssen, Novartis, Bausch, and Pfizer. Dr Lansang has received honoraria and consulting fees from AbbVie, Amgen, Bausch, Celgene, Galderma, Janssen, Lilly, Novartis, Pfizer, Sanofi, UCB, and Valeant.